Raising the profile of Scarlet Therapeutics

“Katja and team did an excellent job communicating our key validation milestone, demonstrating that lab grown universal red blood cells have a half-life matching donated blood, as well as our financing. I was impressed by their proactivity and the targeted media coverage achieved.”

Alistair Irvine
CEO of Scarlet Therapeutics

Objectives

Highlight the value of the company’s innovative lab-grown universal red blood cell-based (RBCs) technology across application areas including treatment, transfusion, and enhancement
Highlight successful close of a £3.2m seed financing round to take the company’s manufactured RBCs into the clinic. Loaded with therapeutic proteins, they will be used to treat rare metabolic diseases

Strategy

Developed messaging around key asset characteristics including that the in vivo survival of the company’s lab-grown universal RBCs is equivalent to donated blood
Drafted press release and accompanying media Q&A and rehearsed responses
Engaged with media under embargo, including an in-person interview at BioTrinity, to tell the story and secure coverage

Results

Secured significant trade-media coverage, including in key trade titles such as BioWorld, European Biotechnology Magazine, Labiotech, and Longevity Technology, and MedNous